Liver

LEAP-002 Long-Term Follow-Up: Further Exploring Lenvatinib Plus Pembrolizumab for Liver Cancer
Dr. Finn discusses the follow-up of LEAP-002 and its clinical implications despite not meeting the primary end points.
Advertisement
Advertisement